Overview

A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This was a Phase III, randomized, double-blind, placebo-controlled study that was conducted at 24 centers in the United States and Canada. 100 adult and pediatric patients with dysfunctional central venous catheters (CVCs) were randomly assigned in a 1:1 ratio to receive an initial dose of either placebo (Arm A) or tenecteplase (Arm B).
Phase:
Phase 3
Details
Lead Sponsor:
Genentech, Inc.
Treatments:
Tenecteplase
Tissue Plasminogen Activator